Lothian NHS Board

Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG



Telephone: 0131 536 9000 www.nhslothian.scot.nhs.uk www.nhslothian.scot.nhs.uk

Date: 29/05/2024

Your Ref:

Our Ref: 8758

Enquiries to: Richard Mutch
Extension: 35687
Direct Line: 0131 465 5687
loth.freedomofinformation@nhs.scot

richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION - DERMATOLOGY PRESCRIBING

I write in response to your request for information in relation to Dermatology prescribing within NHS Lothian.

Question:

- 1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
 - Adalimumab Humira
 - Adalimumab Biosimilar
 - Apremilast
 - Bimekizumab
 - Brodalumab
 - Certolizumab
 - DeucravacitinibDimethyl fumarate
 - Etanercept Enbrel
 - Etanercept Biosimilar
 - Guselkumab
 - Infliximab Remicade
 - Infliximab Biosimilar
 - Ixekizumab
 - Risankizumab
 - Secukinumab
 - Tildrakizumab
 - Ustekinumab









Answer:

February 2024 - April 2024	
CMM (Pharmacy Stock Control) and HEPMA (Inpatient Administrations) Data	
Medication	Patient Count
Adalimumab (Biosimilar)	243
Adalimumab (Humira)	5<
Apremilast	15
Bimekizumab	5<
Brodalumab	5<
Certolizumab Pegol	5<
Deucravacitinib	0
Dimethyl Fumarate	5<
Etanercept (Biosimilar)	13
Etanercept (Enbrel)	5<
Guselkumab	54
Infliximab (Biosimilar)	0
Infliximab (Remicade)	0
Ixekizumab	13
Risankizumab	81
Secukinumab	17
Tildrakizumab	5<
Ustekinumab	40

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

- 2. How many patients were treated in the last 3 months by the Dermatology department for HS (Hidradenitis Suppurativa) ONLY with the following:
 - Adalimumab Humira
 - Adalimumab Biosimilar
 - Bimekizumab
 - Certolizumab
 - Infliximab Remicade

- Infliximab Biosimilar
- Secukinumab
- Ustekinumab

Answer:

We unable to link diagnoses. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI/Pages/default.aspx

Yours sincerely

ALISON MACDONALD Executive Director, Nursing, Midwifery and AHPs

Cc: Chief Executive